Indivior Targeting Listing On NASDAQ For The Spring Of 2023

Indivior PLC INVVY INDV will hold a capital markets day on December 7^th in New York City. The event will be hosted by Mark Crossley, CEO, along with members of the Indivior executive leadership team and will detail the company’s strategic growth plans and roadmap for delivering long-term shareholder value.

Indivior expects SUBLOCADE injection to achieve a net revenue run rate of $1 billion by the end of 2025, driven by its focus on further developing the organized health systems channel and pursuing the large opportunity in the U.S. Justice System. Longer term, based on the expected positive market dynamics for buprenorphine medication-assisted treatment and on continued execution against its organized health systems strategy, Indivior now expects to deliver SUBLOCADE peak potential net revenue of >$1.5 billion.

The company expects to achieve a double-digit percentage net revenue compounded annual growth rate over the medium-term, driven primarily by SUBLOCADE in the United States and growing net revenue contribution from PERSERIS. Within this outlook, which is based on its current business portfolio, Indivior also expects a return to net revenue growth in the rest of the world driven by new products SUBLOCADE and SUBOXONE film. Additionally, the company assumes the U.S. market share of SUBOXONE Film, which it does not promote, will trend towards historical analogs for genericized medicines.

Listing on NASDAQ targeted for the Spring of 2023

At its extraordinary general meeting in September of this year, Indivior received strong support from its shareholders for an additional share listing in the United States. Having carefully evaluated the available options, Indivior has chosen NASDAQ as its U.S. trading venue. The additional listing is expected to elevate Indivior’s profile in the company’s largest market and to attract a broader group of biopharma-focused investors and analysts.

The group reiterates its FY 2022 guidance published on October 27, 2022.

Get your daily dose of cannabis news on Benzinga Cannabis. Don’t miss out on any important developments in the industry.

Photo by Giorgio Trovato on Unsplash